Catalyst
Slingshot members are tracking this event:
FDA approves Novartis' (NVS) BLA for CAR-T drug candidate CTL019—treating pediatrics, young adults with refractory B-cell acute lymphoblastic leukemia—for Priority Review
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 29, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Acute Lymphoblastic Leukemia, Bla, Fda, Car-t, Ctl019, Priority Review
